Navigation Links
Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
Date:10/25/2007

PALO ALTO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) reported positive preclinical data from its ongoing program to develop novel small molecule inhibitors of validated cancer targets including aurora kinases and VEGFR2. The data were presented today at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in San Francisco.

Aurora kinases are enzymes that play a key role in mitosis, or cell division. They are over-expressed in many human cancers, including breast, colon, pancreas, prostate and thyroid cancer, and are associated with carcinogenesis. Several aurora kinase inhibitors are currently under clinical evaluation for the treatment of cancer.

The VEGF receptor 2 (VEGFR2/KDR/Flt-1), a clinically validated target, plays a pivotal role in controlling angiogenesis and metastasis. A single agent that targets both aurora kinases and VEGFR2 may offer advantages of simultaneously attacking the ability of cancer cells to grow and divide while starving existing tumors of needed blood supply.

Telik scientists have identified a class of selective small molecule inhibitors of aurora kinase A and B and VEGFR2. Treatment of human colorectal cancer cells with two of these inhibitors, A60 and EA19, prevented cell division, ultimately leading to cancer cell apoptosis (programmed cell death). These same compounds are potent inhibitors of VEGF-dependent human endothelial cell proliferation. These agents demonstrated significant inhibition of tumor growth in a standard xenograft model of human colorectal cancer.

"These data support the continued development of aurora kinase and VEGFR2 inhibitors," said James G. Keck, Ph.D., vice president, biology research. "We
'/>"/>

SOURCE Telik, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
2. Telik Announces Telcyta Clinical and Preclinical Presentations at AACR Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 /PRNewswire-iReach/ -- It is no secret that ... being overweight or obese gyms and supplement companies are in ... condition is primarily related to dietary issues and a lack ... result of a glandular problem or even a vitamin deficiency. ... vitamin deficiency is a lack of vitamin b12 . ...
(Date:5/20/2013)... 2013   National Community Pharmacists Association (NCPA) ... MBA issued the following statement today regarding a ... D "preferred pharmacy" drug plans , which often ... lowest advertised co-payments: (Logo:  http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... MedPAC , 16 U.S. Senators and ...
(Date:5/20/2013)... 20, 2013 /PRNewswire-iReach/ -- Today at American Society ... Christine Ginocchio discussed Specific Technologies blood ... identification of microorganisms producing bloodstream infection. Dr. Ginocchio ... the Division of Infectious Disease Diagnostics at North ... non-sectarian health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ...
Breaking Medicine Technology:USB12Shots.com Discusses the Possibility of B12 Shots for Weight Loss 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... treatment-failure gout will be reviewed by the Arthritis Advisory Committee ... March 5, 2009 as required for a drug of a ... to the FDA on October 31, 2008 seeking approval to ...
... Stock to trade under new ticker symbol ,CDXP.OB, LA ... Bulletin Board: DSKA) announced today that it has completed ... a result of the name change, the Over-the-Counter Bulletin ... ticker symbol OTCBB: CDXP.OB.James S. Kuo, M.D., Cordex,s Chief ...
Cached Medicine Technology:Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 2Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 3Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 4Duska Therapeutics Completes Corporate Name Change to Cordex Pharma 2Duska Therapeutics Completes Corporate Name Change to Cordex Pharma 3
(Date:5/21/2013)... Romio , an innovative online local ... businesses, announced today that it will be releasing short ... Medical Care is located in Tribeca and Clinton and ... The guarantee of seeing a doctor within 20 ... the neighborhood and a great alternative to long waits ...
(Date:5/21/2013)... AAG Health, the leading age management ... that it has acquired the OligoScan test made by ... advanced spectrophotometry technology, the OligoScan device is capable of ... 14 heavy metals, 20 trace elements (minerals), and oxidative ... substances such as mercury, lead, aluminum, and arsenic, will ...
(Date:5/21/2013)... Alan Mozes HealthDay Reporter , , MONDAY, ... used by millions of people with chronic obstructive ... cardiovascular complications among older patients, a new large ... patients over age 65 who are prescribed long-acting ... beta-agonists (such as Serevent). Both medications are commonly ...
(Date:5/21/2013)... exist in the treatment of non-small cell lung cancer ... large new study. Although most patients with this ... researchers found that blacks were less likely than Hispanics ... of the disease. Hispanics were more likely to undergo ... white patients. "In our study of more than ...
(Date:5/21/2013)... ─ The negative effects of poorly controlled asthma ... urban schoolchildren has been confirmed in a new ... that missed sleep and school absences are important ... is the first to explore the associations between ... time, prospectively, using both objective and subjective ...
Breaking Medicine News(10 mins):Health News:Romio Announces Mini Video Series Featuring Local Business Emergency Medical Care 2Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 2Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 3Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2Health News:Asthma symptoms impair sleep quality and school performance in children 2
... Nev., June 20 Bob Hamilton was named Vice,President ... comes to,Hamilton Medical with a financial background and strong ... Smith Barney,Citigroup Private Bank, Vangaurd and Janus Funds, just ... financial analysis, Hamilton Medical is,looking forward to great things ...
... -- The Damon Runyon Cancer Research Foundation named ... May 2008 Clinical Investigator Award Committee review. ... outstanding early career physician-scientists conducting patient-oriented cancer research ... the nation,s leading scientists and clinicians. Each ...
... American College of Physicians (ACP) today commended the Medicare ... importance of primary care in a well-functioning health-care delivery ... ACP commended MedPAC in a letter to Glen D. ... that advises the U.S. Congress on issues affecting the ...
... about test that has no direct evidence of benefit ... may help reduce lung cancer deaths among current and former ... smoking-related causes, a new study reports. , Researchers ... Minn., entered data from 1,520 current and former smokers who ...
... Blockbusters are not,discovered, they are built! To build ... wisely. The recipe for success continues,to evolve for ... allocation processes that enable them to identify early,winners ... paper "Launching a Blockbuster: The Making,and Marketing of ...
... USAID to Invest US $50 Million over a ... Planning, RESEARCH TRIANGLE PARK, N.C., June 20 ... announced that Family,Health International (FHI) -- a global ... major family planning research project known as,PROGRESS (Program ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards $2.25M to 5 top young clinical investigators 2Health News:Damon Runyon Cancer Research Foundation awards $2.25M to 5 top young clinical investigators 3Health News:American College of Physicians commends MedPAC June 2008 report to Congress 2Health News:American College of Physicians commends MedPAC June 2008 report to Congress 3Health News:CT Screens for Lung Cancer Not a Cure-All 2Health News:Family Health International Awarded USAID 'Progress' Project to Improve Family Planning and Reproductive Health Programs in Developing Countries 2Health News:Family Health International Awarded USAID 'Progress' Project to Improve Family Planning and Reproductive Health Programs in Developing Countries 3
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... perfect mix of powerful, versatile, and innovative ... Palomar StarLux® Pulsed Light and Laser System.,With ... compact base unit so theres no ... treatments., You can choose among Laser, Intense ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
Medicine Products: